(Total Views: 630)
Posted On: 09/21/2020 4:00:04 PM
Post# of 156940
Re: Evil Rabbit #57205
What about HIV ? BLA will be fine it will be taken care of, it’s not like it doesn’t work anymore. It’s very clear to me it will be done at some point.
So we get approved to sell Leronlimab for HIV! What’s the SP for that ? 15-30? We are talking about a buyout at that price and we are right around the corner for approval for HIV? What am I missing?
Buyout gets us to 30 dollars a year sooner let’s say. I know people have been waiting a long time but if I remember correctly we have HIV to treat and possibly cure with a bone marrow transplant patient. Why else would all of those Doctors help cytodyn...... Because it’s an amazing drug !
So anyone who’s selling before 30 that’s fine it makes sense for some longs who’ve been here since .30- 1.50 and I get it.... However, I’m not selling anything under 30-50 maybe not even then.
Let’s be honest, NP can mess covid up ect not get good results with cancer and NASH trials stop enrolling because idk something went wrong.....
Leronlimab is going to still be sold/approved to treat HIV. If that somehow doesn’t workout then maybe I’d be worried we would see .30 or a company failing. I’m more worried I’ll wake up and see 30 and not have a sell order in. Although I’ll be probably fine with that because I’m thinking I’ll wake up one morning and see it trading for over 100 SP.
Yes cancer update would be great ! As far as I’m concerned sounds like an enrollment problem that can be fixed with money or better exposer of the company. Phase 2 for cancer I can see being done without a 1-2 years and phase 3 maybe another 1-2 years depending on how everything plays out in the long run. Maybe was less time.
Cancer is so far away at this point imo as we speak today. I wasn’t here for that. I was here for covid then I saw HIV and cancer. Now my head hurts trying to think of the 100 other things Leronlimab can treat.
I personally can’t wait to see us cure HIV using Leronlimab... Think about that ?!
So we get approved to sell Leronlimab for HIV! What’s the SP for that ? 15-30? We are talking about a buyout at that price and we are right around the corner for approval for HIV? What am I missing?
Buyout gets us to 30 dollars a year sooner let’s say. I know people have been waiting a long time but if I remember correctly we have HIV to treat and possibly cure with a bone marrow transplant patient. Why else would all of those Doctors help cytodyn...... Because it’s an amazing drug !
So anyone who’s selling before 30 that’s fine it makes sense for some longs who’ve been here since .30- 1.50 and I get it.... However, I’m not selling anything under 30-50 maybe not even then.
Let’s be honest, NP can mess covid up ect not get good results with cancer and NASH trials stop enrolling because idk something went wrong.....
Leronlimab is going to still be sold/approved to treat HIV. If that somehow doesn’t workout then maybe I’d be worried we would see .30 or a company failing. I’m more worried I’ll wake up and see 30 and not have a sell order in. Although I’ll be probably fine with that because I’m thinking I’ll wake up one morning and see it trading for over 100 SP.
Yes cancer update would be great ! As far as I’m concerned sounds like an enrollment problem that can be fixed with money or better exposer of the company. Phase 2 for cancer I can see being done without a 1-2 years and phase 3 maybe another 1-2 years depending on how everything plays out in the long run. Maybe was less time.
Cancer is so far away at this point imo as we speak today. I wasn’t here for that. I was here for covid then I saw HIV and cancer. Now my head hurts trying to think of the 100 other things Leronlimab can treat.
I personally can’t wait to see us cure HIV using Leronlimab... Think about that ?!
(6)
(0)
Daniel Rizzo
Federal Whistleblower
Case Numbers:
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
DOD Case #16282
IC IG / 50 U.S.C. §3033
ARPA-H (Advanced Research Projects Agency for Health)
Founder & CEO of FireGate Bioscience
USPTO: Inventor of the HIV Cure Protocol
[/img]https://investorshangout.com/images/MYImages/1472647104_IMG_3103.png[/img]
https://investorshangout.com/images/MYImages/...G_2859.png
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com
https://investorshangout.com/images/MYImages/..._3106.jpeg
https://investorshangout.com/images/MYImages/..._3107.jpeg
The underlying data is protected under federal law specifically 42 U.S.C. § 289b and its implementing regulation, 42 C.F.R. Part 93 through the Office of Research Integrity (askORI) within HHS, and coordinated with the Office of the Secretary / Office of Public Health and Science (OS/OPHS).
- Waiting…
whistleblower_complaints@wyden.senate.gov belongs to Senator Ron Wyden, a senior Democratic U.S. Senator from Oregon.
We are watching YOU……
“This isn’t conspiracy, this is criminal suppression.” - Ohm
https://www.justice.gov/usao-sdny/pr/us-attor...r-programs
https://investorshangout.com/images/MYImages/..._3015.jpeg
???? What Leronlimab Does
• Target: CCR5 receptor (the same receptor people with the CCR5Δ32 mutation lack — like the “Berlin” and “London” patients who were cured after stem cell transplants).
• Effect: By binding CCR5, leronlimab blocks HIV entry into CD4 cells.
• Trial Data:
• In combination therapy trials, ~81% of patients achieved viral loads <50 copies/mL (suppression, not cure).
• As monotherapy, some patients maintained suppression for long stretches (months), but not universally.
⸻
???? Why It Might Be Seen as a “Cure”
• In theory, if you completely block CCR5 on all relevant cells, HIV can’t infect new cells.
• If existing infected reservoirs naturally decay without replenishment, the virus could eventually vanish.
• That’s exactly what happened in the Berlin/London patients — except through stem cell transplants with CCR5Δ32 donors, not a drug.
⸻
???? Why It Hasn’t Been Called a Cure (Yet)
1. HIV Reservoirs Persist
Leronlimab blocks new infection, but it doesn’t flush latent virus from cells. Once treatment stops, those reservoirs can reignite infection.
2. CCR5-Independent Pathways
Some HIV strains use CXCR4 or dual-tropism (CCR5 + CXCR4). Leronlimab won’t stop those.
3. Clinical Conservatism
Researchers avoid using the word “cure” unless patients remain off all therapy with no viral rebound for years. Leronlimab hasn’t shown that in trials.
⸻
???? So Could It Alone Cure HIV?
• In select cases (if someone’s virus is purely CCR5-tropic and their reservoirs naturally decay): maybe.
• But in the general population, it’s unlikely as a monotherapy cure. More realistic is using it as part of a cure combo approach…
Federal Whistleblower
Case Numbers:
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
DOD Case #16282
IC IG / 50 U.S.C. §3033
ARPA-H (Advanced Research Projects Agency for Health)
Founder & CEO of FireGate Bioscience
USPTO: Inventor of the HIV Cure Protocol
[/img]https://investorshangout.com/images/MYImages/1472647104_IMG_3103.png[/img]
https://investorshangout.com/images/MYImages/...G_2859.png
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com
https://investorshangout.com/images/MYImages/..._3106.jpeg
https://investorshangout.com/images/MYImages/..._3107.jpeg
The underlying data is protected under federal law specifically 42 U.S.C. § 289b and its implementing regulation, 42 C.F.R. Part 93 through the Office of Research Integrity (askORI) within HHS, and coordinated with the Office of the Secretary / Office of Public Health and Science (OS/OPHS).
- Waiting… whistleblower_complaints@wyden.senate.gov belongs to Senator Ron Wyden, a senior Democratic U.S. Senator from Oregon.
We are watching YOU……
“This isn’t conspiracy, this is criminal suppression.” - Ohm
https://www.justice.gov/usao-sdny/pr/us-attor...r-programs
https://investorshangout.com/images/MYImages/..._3015.jpeg
???? What Leronlimab Does
• Target: CCR5 receptor (the same receptor people with the CCR5Δ32 mutation lack — like the “Berlin” and “London” patients who were cured after stem cell transplants).
• Effect: By binding CCR5, leronlimab blocks HIV entry into CD4 cells.
• Trial Data:
• In combination therapy trials, ~81% of patients achieved viral loads <50 copies/mL (suppression, not cure).
• As monotherapy, some patients maintained suppression for long stretches (months), but not universally.
⸻
???? Why It Might Be Seen as a “Cure”
• In theory, if you completely block CCR5 on all relevant cells, HIV can’t infect new cells.
• If existing infected reservoirs naturally decay without replenishment, the virus could eventually vanish.
• That’s exactly what happened in the Berlin/London patients — except through stem cell transplants with CCR5Δ32 donors, not a drug.
⸻
???? Why It Hasn’t Been Called a Cure (Yet)
1. HIV Reservoirs Persist
Leronlimab blocks new infection, but it doesn’t flush latent virus from cells. Once treatment stops, those reservoirs can reignite infection.
2. CCR5-Independent Pathways
Some HIV strains use CXCR4 or dual-tropism (CCR5 + CXCR4). Leronlimab won’t stop those.
3. Clinical Conservatism
Researchers avoid using the word “cure” unless patients remain off all therapy with no viral rebound for years. Leronlimab hasn’t shown that in trials.
⸻
???? So Could It Alone Cure HIV?
• In select cases (if someone’s virus is purely CCR5-tropic and their reservoirs naturally decay): maybe.
• But in the general population, it’s unlikely as a monotherapy cure. More realistic is using it as part of a cure combo approach…
